Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates

• Main Authors: Cressey T., Punyawudho B., Le Coeur S., Jourdain G., Saenjum C., Capparelli E., Jittayanun K., Phanomcheong S., Luvira A., Borkird T., Puangsombat A., Aarons L., Sukrakanchana P., Urien S., Lallemant M., Sangsawang S., Achalapong J., Preedisripipat K., Putiyanun C., Wanchaitanawong V., Yuthavisuthi P., Ngampiyaskul C., Kanjanavikai P., Chotivanich N., Hongsiriwon S., Suwankornsakul W., Sreshthatat P., Kanjanasing A., Kwanchaipanich R., Rawangban B., Santadusit S., Jarupanich T., Warachit B., Siriwachirachai T., Rojanakarin P., Vivatpatanakul K., Hanpinitsak S., Wanasiri P., Srirojana S., Kongpanichkul R., Bunjongpak S., Sabsanong P., Liampongsabuddhi P., Pongdetudom K., Khamja P., Akarathum N., Phonin S., Limpitikul W., Jungpipun J., Petprakorp R., Mahattanan S., Kotchawet S., Pilalai T.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85025687300&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40175

© Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. Background: Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optima...